Ascendis Pharma A/S (ASND) Stock Price Today
Aura AI Summary
Key Stats
- $18.08BMarket Cap
- -Volume
- HealthSector
- $277.1852W High
- $163.3252W Low
- -Typical Hold Time
- $18.45BEnterprise Value
- -Div Yield
- -Trading Activity
Track Ascendis Pharma A/S (ASND) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Ascendis Pharma A/S has traded between a low of $163.32 and a high of $277.18, highlighting its annual price range. Buy and sell Ascendis Pharma A/S shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Most Recent News
Document AI market to nearly double to $27.62B by 2030, driven by AI and automation in regulated industries.
The Document AI market is forecasted to grow from $14.66 billion in 2025 to $27.62 billion by 2030, at a CAGR of 13.5%. This growth is fueled by organizations adopting AI technologies like intelligent document processing, generative AI, and workflow ...

AI in orthopedic surgery market to hit $0.87B by 2030 with 27.2% CAGR, driven by tech advances and rising musculoskeletal disorders
The AI in orthopedic surgery market is projected to grow from $0.26 billion in 2025 to $0.87 billion by 2030, at a CAGR of 27.2%. Growth is fueled by increased orthopedic surgeries, innovations in medical imaging, adoption of minimally invasive techn...

Generative AI in drug discovery market to reach $0.86B by 2030, growing at 27% CAGR driven by faster drug development and AI advances
The generative AI market in drug discovery is expanding rapidly, expected to grow from $0.33 billion in 2026 to $0.86 billion by 2030 with a 27% CAGR. Growth is fueled by rising drug development costs, advances in AI technologies like deep learning, ...
